Hiroyuki Yoda
Research Subjects
Hiroyuki Yoda has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Nobuko Koshikawa
Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute Chiba Japan
17 shared publicationsTakayoshi Watanabe
16 shared publicationsTakahiro Inoue
15 shared publicationsYoshinao Shinozaki
Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute Chiba Japan
15 shared publicationsAtsushi Takatori
12 shared publicationsHiroki Nagase
10 shared publications
Latest Publications
- 14 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (9)
Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma
Neuroblastomas are highly heterogeneous tumors originating from neural crest-derived cells destined to form the sympathetic nervous system. Nearly half of high-risk tumors present with amplification of the MYCN proto-oncogene. Here, we describe a Mycn-driven, transplantable, non-germline, genetically engineered mouse model (Mycn-nGEMM). Mycn-nGEMM tumors recapitulate the immune-evasive, macrophage-rich tumor microenvironment of high-risk, MYCN-amplified human neuroblastoma. Treatment of tumor-bearing mice with anti–PD-L1, but not anti-PD-1 or anti-CTLA-4, inhibited tumor growth, profoundly remodeling the tumor microenvironment by depleting anti-inflammatory macrophages and increasing T cell infiltration. Surprisingly, while tumor cells showed low expression of PD-L1, anti-inflammatory macrophages from both murine and human neuroblastoma expressed PD-L1. We identified cytokines, including macrophage migration inhibitory factor, secreted by the Mycn-nGEMM cancer cells that drive expression of PD-L1 on macrophages. Combining anti–PD-L1 with CD40 agonist antibodies further improved survival in Mycn-nGEMM mice, demonstrating the potential for myeloid-targeting immunotherapies to overcome inhibitory barriers in immune-evasive neuroblastoma.
- 14 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (9)
Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma
Neuroblastomas are highly heterogeneous tumors originating from neural crest-derived cells destined to form the sympathetic nervous system. Nearly half of high-risk tumors present with amplification of the MYCN proto-oncogene. Here, we describe a Mycn-driven, transplantable, non-germline, genetically engineered mouse model (Mycn-nGEMM). Mycn-nGEMM tumors recapitulate the immune-evasive, macrophage-rich tumor microenvironment of high-risk, MYCN-amplified human neuroblastoma. Treatment of tumor-bearing mice with anti–PD-L1, but not anti-PD-1 or anti-CTLA-4, inhibited tumor growth, profoundly remodeling the tumor microenvironment by depleting anti-inflammatory macrophages and increasing T cell infiltration. Surprisingly, while tumor cells showed low expression of PD-L1, anti-inflammatory macrophages from both murine and human neuroblastoma expressed PD-L1. We identified cytokines, including macrophage migration inhibitory factor, secreted by the Mycn-nGEMM cancer cells that drive expression of PD-L1 on macrophages. Combining anti–PD-L1 with CD40 agonist antibodies further improved survival in Mycn-nGEMM mice, demonstrating the potential for myeloid-targeting immunotherapies to overcome inhibitory barriers in immune-evasive neuroblastoma.
- Open Access
- 7 March 2025
- Published by Wiley in Cancer Science
- Vol. 116 (6) , 1691-1702
ATR Inhibition Synergizes With Alkylating PI Polyamide Targeting MYCN by Suppressing DNA Repair in MYCN‐Amplified Neuroblastoma
Amplification of MYCN is a major oncogenic driver of high‐risk neuroblastomas. We previously developed CCC‐002, a MYCN‐selective pyrrole‐imidazole polyamide conjugated to a DNA alkylating agent. Administration of CCC‐002 to MYCN‐amplified (MYCN‐amp) neuroblastoma cells triggered the activation of DNA damage responses. Here, we demonstrated that among the DNA damage response inhibitors, ataxia telangiectasia and Rad3‐related (ATR) inhibitors synergized with CCC‐002 to suppress DNA repair‐related genes and induce apoptosis in MYCN‐amp neuroblastoma cells. A synergistic antitumor effect was verified in an SK‐N‐BE(2) xenograft mouse model, in which the combined use of CCC‐002 and ATR inhibitor at low doses significantly inhibited tumor progression. Notably, SK‐N‐BE(2) and SK‐N‐DZ cells, which showed ATM activation after CCC‐002 treatment, exhibited high sensitivity to the combined treatment of ATR inhibitors. Comprehensive analysis of the gene expression profiles revealed that the combination treatment upregulated apoptosis‐related pathways and downregulated DNA repair‐related pathways. After the combined treatment of CCC‐002 and ATR inhibitor, MYCN‐amp cells showed less FISH probe signal and mRNA expression of MYCN, which was accompanied by an increase in DNA damage markers in the genomic region of MYCN, highlighting that ATR inhibitors synergize with CCC‐002 and play a crucial role in the development of a novel MYCN‐targeting therapy for MYCN‐amp neuroblastoma.
- 7 March 2025
- Published by Wiley in Cancer Science
- Vol. 116 (6) , 1691-1702
Open AccessATR Inhibition Synergizes With Alkylating PI Polyamide Targeting MYCN by Suppressing DNA Repair in MYCN‐Amplified Neuroblastoma
Amplification of MYCN is a major oncogenic driver of high‐risk neuroblastomas. We previously developed CCC‐002, a MYCN‐selective pyrrole‐imidazole polyamide conjugated to a DNA alkylating agent. Administration of CCC‐002 to MYCN‐amplified (MYCN‐amp) neuroblastoma cells triggered the activation of DNA damage responses. Here, we demonstrated that among the DNA damage response inhibitors, ataxia telangiectasia and Rad3‐related (ATR) inhibitors synergized with CCC‐002 to suppress DNA repair‐related genes and induce apoptosis in MYCN‐amp neuroblastoma cells. A synergistic antitumor effect was verified in an SK‐N‐BE(2) xenograft mouse model, in which the combined use of CCC‐002 and ATR inhibitor at low doses significantly inhibited tumor progression. Notably, SK‐N‐BE(2) and SK‐N‐DZ cells, which showed ATM activation after CCC‐002 treatment, exhibited high sensitivity to the combined treatment of ATR inhibitors. Comprehensive analysis of the gene expression profiles revealed that the combination treatment upregulated apoptosis‐related pathways and downregulated DNA repair‐related pathways. After the combined treatment of CCC‐002 and ATR inhibitor, MYCN‐amp cells showed less FISH probe signal and mRNA expression of MYCN, which was accompanied by an increase in DNA damage markers in the genomic region of MYCN, highlighting that ATR inhibitors synergize with CCC‐002 and play a crucial role in the development of a novel MYCN‐targeting therapy for MYCN‐amp neuroblastoma.
- 9 September 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (2) , 383-397
EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma
Co-amplification of EGFR and EGFRvIII, a tumor-specific truncation mutant of EGFR, represent hallmark genetic lesions in glioblastoma. We used phospho-proteomics, RNA-sequencing, TCGA data and glioblastoma cell culture and mouse models to study the signal transduction mediated by EGFR and EGFRvIII. We report that EGFR and EGFRvIII stimulate the innate immune defense receptor Toll-like Receptor 2 (TLR2); and that knockout of TLR2 dramatically improved survival in orthotopic glioblastoma xenografts. EGFR and EGFRvIII activated TLR2 in a ligand-independent manner, promoting tumor growth and immune evasion. We show that EGFR and EGFRvIII cooperate to activate the Rho-associated protein kinase ROCK2, which modulated malignant progression both by activating TLR2 and WNT signaling, and through remodeling the tumor microenvironment. Together, our findings show that EGFR and EGFRvIII cooperate to drive tumor progression through ROCK2 and downstream WNT-β-catenin/TLR2 signaling pathways.
- 9 September 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (2) , 383-397
EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma
Co-amplification of EGFR and EGFRvIII, a tumor-specific truncation mutant of EGFR, represent hallmark genetic lesions in glioblastoma. We used phospho-proteomics, RNA-sequencing, TCGA data and glioblastoma cell culture and mouse models to study the signal transduction mediated by EGFR and EGFRvIII. We report that EGFR and EGFRvIII stimulate the innate immune defense receptor Toll-like Receptor 2 (TLR2); and that knockout of TLR2 dramatically improved survival in orthotopic glioblastoma xenografts. EGFR and EGFRvIII activated TLR2 in a ligand-independent manner, promoting tumor growth and immune evasion. We show that EGFR and EGFRvIII cooperate to activate the Rho-associated protein kinase ROCK2, which modulated malignant progression both by activating TLR2 and WNT signaling, and through remodeling the tumor microenvironment. Together, our findings show that EGFR and EGFRvIII cooperate to drive tumor progression through ROCK2 and downstream WNT-β-catenin/TLR2 signaling pathways.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Amplification of MYCN plays a pivotal role in multiple types of tumors and correlates with poor prognosis in high-risk neuroblastoma. Despite recent advances in the treatment of neuroblastoma, no approaches directly target the master oncogene MYCN. Difficulties in targeting the MYCN protein inspired us to develop a new gene-level–inhibitory strategy using a sequence-specific gene regulator. Here, we generated a MYCN-targeting pyrrole-imidazole (PI) polyamide, MYCN-A3, which directly binds to and alkylates DNA at homing motifs within the MYCN transcript. Pharmacologic suppression of MYCN inhibited the proliferation of cancer cells harboring MYCN amplification compared with MYCN nonamplified cancer cells. In neuroblastoma xenograft mouse models, MYCN-A3 specifically downregulated MYCN expression and suppressed tumor progression with no detectable adverse effects and resulted in prolonged overall survival. Moreover, treatment with MYCN-A3, but not MYCN nontargeting PI polyamide, precipitated a copy number reduction of MYCN in neuroblastoma cells with MYCN amplification. These findings suggest that directly targeting MYCN with MYCN-A3 is a novel therapeutic approach to reduce copy number of the MYCN gene for MYCN-amplified neuroblastoma.Significance:This study presents a novel approach to drugging an amplified oncogene by showing that targeting gene amplification of MYCN suppresses MYCN expression and neuroblastoma growth.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Amplification of MYCN plays a pivotal role in multiple types of tumors and correlates with poor prognosis in high-risk neuroblastoma. Despite recent advances in the treatment of neuroblastoma, no approaches directly target the master oncogene MYCN. Difficulties in targeting the MYCN protein inspired us to develop a new gene-level–inhibitory strategy using a sequence-specific gene regulator. Here, we generated a MYCN-targeting pyrrole-imidazole (PI) polyamide, MYCN-A3, which directly binds to and alkylates DNA at homing motifs within the MYCN transcript. Pharmacologic suppression of MYCN inhibited the proliferation of cancer cells harboring MYCN amplification compared with MYCN nonamplified cancer cells. In neuroblastoma xenograft mouse models, MYCN-A3 specifically downregulated MYCN expression and suppressed tumor progression with no detectable adverse effects and resulted in prolonged overall survival. Moreover, treatment with MYCN-A3, but not MYCN nontargeting PI polyamide, precipitated a copy number reduction of MYCN in neuroblastoma cells with MYCN amplification. These findings suggest that directly targeting MYCN with MYCN-A3 is a novel therapeutic approach to reduce copy number of the MYCN gene for MYCN-amplified neuroblastoma.Significance:This study presents a novel approach to drugging an amplified oncogene by showing that targeting gene amplification of MYCN suppresses MYCN expression and neuroblastoma growth.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Information from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Supplementary Materials and Methods and Supplementary Figure Legends
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Information from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Supplementary Materials and Methods and Supplementary Figure Legends
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Information from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Supplementary Materials and Methods and Supplementary Figure Legends
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Information from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Supplementary Materials and Methods and Supplementary Figure Legends
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Supplementary Figure S1. MYCN-amplified neuroblastoma cell lines are addicted to MYCN. Supplementary Figure S2. Cytotoxic evaluation of PI polyamides targeting the MYCN gene. Supplementary Figure S3. Direct alkylation of the targeted DNA of MYCN gene. Supplementary Figure S4. MYCN-A3 and MYCN-A4 inhibit MYCN expression and cell proliferation in MYCN-amplified neuroblastoma cell lines. Supplementary Figure S5. Global impact of MYCN-A3 on gene expression in MYCN-amplified neuroblastoma cells is comparable to that of CRISPR/Cas9 targeting MYCN. Supplementary Figure S6. MYCN-A3 induces cell cycle arrest and the expression levels of p53 family genes in neuroblastoma cell lines. Supplementary Figure S7. MYCN-A3 suppresses tumor growth in human neuroblastoma xenograft mouse models. Supplementary Figure S8. Pharmacological effects of MYCN-A3 on human MYCN-amplified neuroblastoma xenograft models in vivo. Supplementary Figure S9. MYCN-A3 affects the MYCN gene loci and not non-targeted gene loci.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Supplementary Figure S1. MYCN-amplified neuroblastoma cell lines are addicted to MYCN. Supplementary Figure S2. Cytotoxic evaluation of PI polyamides targeting the MYCN gene. Supplementary Figure S3. Direct alkylation of the targeted DNA of MYCN gene. Supplementary Figure S4. MYCN-A3 and MYCN-A4 inhibit MYCN expression and cell proliferation in MYCN-amplified neuroblastoma cell lines. Supplementary Figure S5. Global impact of MYCN-A3 on gene expression in MYCN-amplified neuroblastoma cells is comparable to that of CRISPR/Cas9 targeting MYCN. Supplementary Figure S6. MYCN-A3 induces cell cycle arrest and the expression levels of p53 family genes in neuroblastoma cell lines. Supplementary Figure S7. MYCN-A3 suppresses tumor growth in human neuroblastoma xenograft mouse models. Supplementary Figure S8. Pharmacological effects of MYCN-A3 on human MYCN-amplified neuroblastoma xenograft models in vivo. Supplementary Figure S9. MYCN-A3 affects the MYCN gene loci and not non-targeted gene loci.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Table S1. IC50 values of MYCN-A3-treated 27 cancer cell lines. Table S2. List of Kyoto Encyclopedia Genes and Genome (KEGG) pathways and their relative group-wise expression differences between MYCN-A3 and MYCNcr-a.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Table S1. IC50 values of MYCN-A3-treated 27 cancer cell lines. Table S2. List of Kyoto Encyclopedia Genes and Genome (KEGG) pathways and their relative group-wise expression differences between MYCN-A3 and MYCNcr-a.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Table S1. IC50 values of MYCN-A3-treated 27 cancer cell lines. Table S2. List of Kyoto Encyclopedia Genes and Genome (KEGG) pathways and their relative group-wise expression differences between MYCN-A3 and MYCNcr-a.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Table S1. IC50 values of MYCN-A3-treated 27 cancer cell lines. Table S2. List of Kyoto Encyclopedia Genes and Genome (KEGG) pathways and their relative group-wise expression differences between MYCN-A3 and MYCNcr-a.